<SEC-DOCUMENT>0001193125-18-073902.txt : 20180308
<SEC-HEADER>0001193125-18-073902.hdr.sgml : 20180308
<ACCEPTANCE-DATETIME>20180307212433
ACCESSION NUMBER:		0001193125-18-073902
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20180307
ITEM INFORMATION:		Other Events
FILED AS OF DATE:		20180308
DATE AS OF CHANGE:		20180307

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CVS HEALTH Corp
		CENTRAL INDEX KEY:			0000064803
		STANDARD INDUSTRIAL CLASSIFICATION:	RETAIL-DRUG STORES AND PROPRIETARY STORES [5912]
		IRS NUMBER:				050494040
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-01011
		FILM NUMBER:		18674879

	BUSINESS ADDRESS:	
		STREET 1:		ONE CVS DR.
		CITY:			WOONSOCKET
		STATE:			RI
		ZIP:			02895
		BUSINESS PHONE:		4017651500

	MAIL ADDRESS:	
		STREET 1:		ONE CVS DR.
		CITY:			WOONSOCKET
		STATE:			RI
		ZIP:			02895

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CVS CAREMARK CORP
		DATE OF NAME CHANGE:	20070509

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CVS/CAREMARK CORP
		DATE OF NAME CHANGE:	20070322

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CVS CORP
		DATE OF NAME CHANGE:	19970128
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d535508d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C.&nbsp;20549 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B><FONT
STYLE="white-space:nowrap">FORM&nbsp;8-K</FONT> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): March&nbsp;7, 2018 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g535508g04p51.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>CVS HEALTH CORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Exact Name of Registrant as Specified in its Charter) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>(State or Other Jurisdiction of<BR>Incorporation)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-01011</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">05-0494040</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Commission File Number)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(IRS Employer Identification No.)</B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center"><B>One CVS Drive</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center"><B>Woonsocket, Rhode Island</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>02895</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of Principal Executive Offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code:&nbsp;(401)
<FONT STYLE="white-space:nowrap">765-1500</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the <FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9745;</TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to <FONT STYLE="white-space:nowrap">Rule&nbsp;14a-12</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to <FONT STYLE="white-space:nowrap">Rule&nbsp;14d-2(b)&nbsp;under</FONT> the Exchange Act (17 CFR
<FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to <FONT STYLE="white-space:nowrap">Rule&nbsp;13e-4(c)&nbsp;under</FONT> the Exchange Act (17 CFR
<FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as
defined in as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of
this chapter). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company &nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange Act.&nbsp;&nbsp;&nbsp;&#9744; </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;8.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Other Events. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As previously disclosed and reported in the Current Report on Form <FONT
STYLE="white-space:nowrap">8-K</FONT> filed by CVS Health Corporation, a Delaware corporation (&#147;<U>CVS Health</U>&#148;), on December&nbsp;5, 2017 with the Securities and Exchange Commission (the &#147;<U>SEC</U>&#148;), on December&nbsp;3,
2017, CVS Health, Aetna Inc., a Pennsylvania corporation (&#147;<U>Aetna</U>&#148;), and Hudson Merger Sub Corp., a Pennsylvania corporation and a wholly-owned subsidiary of CVS Health (&#147;<U>Merger Sub</U>&#148;), entered into an Agreement and
Plan of Merger (the &#147;<U>Merger Agreement</U>&#148;) pursuant to which, subject to the satisfaction or waiver of certain conditions, Merger Sub will be merged with and into Aetna, with Aetna surviving the merger as a wholly-owned subsidiary of
CVS Health (the &#147;<U>Merger</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;15, 2018, a purported CVS Health stockholder filed a putative class action
complaint challenging the Merger in the Superior Court of the State of Rhode Island, Providence County, against the individual members of the CVS Health board of directors (the &#147;<U>CVS Health Board</U>&#148;) and CVS Health. The complaint is
captioned <I>Gawrych v. Merlo et al</I>., case number <FONT STYLE="white-space:nowrap">PC-2018-0964</FONT> (the &#147;<U>Action</U>&#148;). The Action generally alleges, among other things, that the members of the CVS Health Board breached their
fiduciary duties by negotiating and entering into the Merger Agreement and CVS Health and the CVS Health Board failed to disclose material information in a preliminary joint proxy statement/prospectus relating to the Merger filed by CVS Health with
the SEC on February&nbsp;5, 2018 on Form <FONT STYLE="white-space:nowrap">S-4,</FONT> the definitive version of which was filed by CVS Health with the SEC on February&nbsp;9, 2018 and first mailed to CVS Health stockholders on or about
February&nbsp;12, 2018 (the &#147;<U>Joint Proxy Statement/Prospectus</U>&#148;). The Action seeks, among other things, declaratory and injunctive relief, preliminary injunctive relief prohibiting or delaying the defendants from consummating the
Merger, other forms of equitable relief and unspecified amounts of damages, as well as costs and attorneys&#146; fees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CVS Health
believes that the claims asserted in the Action are without merit and no supplemental disclosure is required under applicable law. However, in order to avoid the risk of adverse effect or delay in connection with the transaction and to minimize the
costs, risks and uncertainties inherent in litigation, and without admitting any liability or wrongdoing, CVS Health has determined to voluntarily supplement the Joint Proxy Statement/Prospectus as described in this Current Report on Form <FONT
STYLE="white-space:nowrap">8-K</FONT> to address claims asserted in the Action, and the plaintiff in the Action has agreed to voluntarily dismiss the Action in light of, among other things, the supplemental disclosure. Nothing in this Current Report
on Form <FONT STYLE="white-space:nowrap">8-K</FONT> shall be deemed an admission of the legal necessity or materiality under applicable laws of any of the disclosures set forth herein. To the contrary, CVS Health specifically denies all allegations
in the Action that any additional disclosure was or is required. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Supplemental Disclosures </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The additional disclosures in this Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> supplement the disclosures contained in,
and should be read in conjunction with, the Joint Proxy Statement/Prospectus, which should be read in its entirety. To the extent that information in this Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> differs from or updates
information contained in the Joint Proxy Statement/Prospectus, the information in this Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> shall supersede or supplement the information in the Joint Proxy Statement/Prospectus.
Capitalized terms used herein, but not otherwise defined, shall have the meanings ascribed to such terms in the Joint Proxy Statement/Prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The
disclosure under the heading &#147;Background of the Merger&#148; is hereby supplemented by adding the following sentence at the end of the second paragraph on page 92 of the Joint Proxy Statement/Prospectus: </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After reviewing the potential transactions with the three managed care companies, the CVS Health board of directors determined that a
transaction with Aetna presented a more favorable value creation opportunity for CVS Health&#146;s stockholders than the potential value that may have resulted from potential strategic transactions with the two other managed care companies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The disclosure under the heading &#147;Background of the Merger&#148; is hereby supplemented by adding the following sentence after the fourth sentence in
the fifth paragraph on page 98 of the Joint Proxy Statement/Prospectus: </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The CVS Health board of directors selected Barclays and
Goldman Sachs as CVS Health&#146;s financing sources in connection with the merger based on, among other things, each of the banks&#146; reputations as internationally recognized financial institutions, their experience and familiarity with CVS
Health and the industries in which CVS Health and Aetna operate, their familiarity with the proposed transaction with Aetna, and their familiarity and experience with financings for similar transactions of the type and size to be provided in
connection with the merger, including with financing transactions with comparable terms and structure. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The disclosure under the heading &#147;Opinion of Barclays Capital Inc.&#148; is hereby supplemented by adding
the following sentence at the end of the first paragraph starting on page 132 of the Joint Proxy Statement/Prospectus: </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the
market close on November&nbsp;8, 2017, Barclays held a net long position of less than 1.0% of the outstanding Aetna common shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The disclosure
under the heading &#147;Opinion of Goldman Sachs&nbsp;&amp; Co. LLC&#148; is hereby supplemented by adding the following sentence after the second sentence in the first paragraph starting on page 134 of the Joint Proxy Statement/Prospectus: </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date of its opinion, none of Goldman Sachs&#146; Investment Banking Division, funds in which Goldman Sachs&#146; Investment Banking
Division had a direct investment, or funds managed by Goldman Sachs&#146; Merchant Banking Division had a direct equity investment in Aetna. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Offer or Solicitation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This communication is for informational purposes only and not intended to and does not constitute an offer to subscribe for, buy or sell, the solicitation of
an offer to subscribe for, buy or sell or an invitation to subscribe for, buy or sell any securities or the solicitation of any vote or approval in any jurisdiction pursuant to or in connection with the proposed transaction or otherwise, nor shall
there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section&nbsp;10 of the Securities Act of
1933, as amended, and otherwise in accordance with applicable law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional Information and Where to Find It </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the proposed transaction between CVS Health Corporation (&#147;CVS Health&#148;) and Aetna Inc. (&#147;Aetna&#148;), on February&nbsp;9,
2018, CVS Health filed with the Securities and Exchange Commission (the &#147;SEC&#148;) an amendment to the registration statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> that was originally filed on January&nbsp;4, 2018. The
registration statement includes a joint proxy statement of CVS Health and Aetna that also constitutes a prospectus of CVS Health. The registration statement was declared effective by the SEC on February&nbsp;9, 2018, and CVS Health and Aetna
commenced mailing the definitive joint proxy statement/prospectus to stockholders of CVS Health and shareholders of Aetna on or about February&nbsp;12, 2018. INVESTORS AND SECURITY HOLDERS OF CVS HEALTH AND AETNA ARE URGED TO READ THE DEFINITIVE
JOINT PROXY STATEMENT/PROSPECTUS AND OTHER DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION. Investors and security holders may obtain free copies of the
registration statement and the definitive joint proxy statement/prospectus and other documents filed with the SEC by CVS Health or Aetna through the website maintained by the SEC at http://www.sec.gov. Copies of the documents filed with the SEC by
CVS Health are available free of charge within the Investors section of CVS Health&#146;s Web site at http://www.cvshealth.com/investors or by contacting CVS Health&#146;s Investor Relations Department at <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">800-201-0938.</FONT></FONT> Copies of the documents filed with the SEC by Aetna are available free of charge on Aetna&#146;s internet website at http://www.Aetna.com or by contacting Aetna&#146;s Investor Relations
Department at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">860-273-0896.</FONT></FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Participants in the Solicitation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CVS Health, Aetna, their respective directors and certain of their respective executive officers may be considered participants in the solicitation of proxies
in connection with the proposed transaction. Information about the directors and executive officers of CVS Health is set forth in its Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2017, which
was filed with the SEC on February&nbsp;14, 2018, its proxy statement for its 2017 annual meeting of stockholders, which was filed with the SEC on March&nbsp;31, 2017, and certain of its Current Reports on Form
<FONT STYLE="white-space:nowrap">8-K.</FONT> Information about the directors and executive officers of Aetna is set forth in its Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2017, which was
filed with the SEC on February&nbsp;23, 2018, its proxy statement for its 2017 annual meeting of shareholders, which was filed with the SEC on April&nbsp;7, 2017, and certain of its Current Reports on Form
<FONT STYLE="white-space:nowrap">8-K.</FONT> Other information regarding the participants in the proxy solicitations and a description of their direct and indirect interests, by security holdings or otherwise, are contained in the definitive joint
proxy statement/prospectus filed with the SEC and other relevant materials to be filed with the SEC when they become available. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cautionary Statement
Regarding Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Private Securities Litigation Reform Act of 1995 (the &#147;Reform Act&#148;) provides a safe harbor for
forward-looking statements made by or on behalf of CVS Health or Aetna. This communication may contain forward-looking statements within the meaning of the Reform Act. You can generally identify forward-looking statements by the use of
forward-looking terminology such as &#147;anticipate,&#148; &#147;believe,&#148; &#147;can,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;estimate,&#148; &#147;evaluate,&#148; &#147;expect,&#148; &#147;explore,&#148; &#147;forecast,&#148;
&#147;guidance,&#148; &#147;intend,&#148; &#147;likely,&#148; &#147;may,&#148; &#147;might,&#148; &#147;outlook,&#148; &#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;probable,&#148; &#147;project,&#148; &#147;seek,&#148;
&#147;should,&#148; &#147;view,&#148; or &#147;will,&#148; or the negative thereof or other variations thereon or comparable terminology. These forward-looking statements are only predictions and involve known and unknown risks and uncertainties,
many of which are beyond CVS Health&#146;s and Aetna&#146;s control. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Statements in this communication regarding CVS Health and Aetna that are forward-looking, including CVS
Health&#146;s and Aetna&#146;s projections as to the closing date for the pending acquisition of Aetna (the &#147;transaction&#148;), the extent of, and the time necessary to obtain, the regulatory approvals required for the transaction, the
anticipated benefits of the transaction, the impact of the transaction on CVS Health&#146;s and Aetna&#146;s businesses, the expected terms and scope of the expected financing for the transaction, the ownership percentages of CVS Health&#146;s
common stock of CVS Health stockholders and Aetna shareholders at closing, the aggregate amount of indebtedness of CVS Health following the closing of the transaction, CVS Health&#146;s expectations regarding debt repayment and its debt to capital
ratio following the closing of the transaction, CVS Health&#146;s and Aetna&#146;s respective share repurchase programs and ability and intent to declare future dividend payments, the number of prescriptions used by people served by the combined
companies&#146; pharmacy benefit business, the synergies from the transaction, and CVS Health&#146;s, Aetna&#146;s and/or the combined company&#146;s future operating results, are based on CVS Health&#146;s and Aetna&#146;s managements&#146;
estimates, assumptions and projections, and are subject to significant uncertainties and other factors, many of which are beyond their control. In particular, projected financial information for the combined businesses of CVS Health and Aetna is
based on estimates, assumptions and projections and has not been prepared in conformance with the applicable accounting requirements of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> relating to pro forma financial information, and the
required pro forma adjustments have not been applied and are not reflected therein. None of this information should be considered in isolation from, or as a substitute for, the historical financial statements of CVS Health and Aetna. Important risk
factors related to the transaction could cause actual future results and other future events to differ materially from those currently estimated by management, including, but not limited to: the timing to consummate the proposed transaction; the
risk that a regulatory approval that may be required for the proposed transaction is delayed, is not obtained or is obtained subject to conditions that are not anticipated; the risk that a condition to the closing of the proposed transaction may not
be satisfied; the outcome of litigation related to the transaction; the ability to achieve the synergies and value creation contemplated; CVS Health&#146;s ability to promptly and effectively integrate Aetna&#146;s businesses; and the diversion of
and attention of management of both CVS Health and Aetna on transaction-related issues. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, this communication may contain forward-looking
statements regarding CVS Health&#146;s or Aetna&#146;s respective businesses, financial condition and results of operations. These forward-looking statements also involve risks, uncertainties and assumptions, some of which may not be presently known
to CVS Health or Aetna or that they currently believe to be immaterial also may cause CVS Health&#146;s or Aetna&#146;s actual results to differ materially from those expressed in the forward-looking statements, adversely impact their respective
businesses, CVS Health&#146;s ability to complete the transaction and/or CVS Health&#146;s ability to realize the expected benefits from the transaction. Should any risks and uncertainties develop into actual events, these developments could have a
material adverse effect on the transaction and/or CVS Health or Aetna, CVS Health&#146;s ability to successfully complete the transaction and/or realize the expected benefits from the transaction. Additional information concerning these risks,
uncertainties and assumptions can be found in CVS Health&#146;s and Aetna&#146;s respective filings with the SEC, including the risk factors discussed in &#147;Item 1.A. Risk Factors&#148; in CVS Health&#146;s and Aetna&#146;s most recent Annual
Reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> as updated by their Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and future filings with the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You are cautioned not to place undue reliance on CVS Health&#146;s and Aetna&#146;s forward-looking statements. These forward-looking statements are and will
be based upon management&#146;s then-current views and assumptions regarding future events and operating performance, and are applicable only as of the dates of such statements. Neither CVS Health nor Aetna assumes any duty to update or revise
forward-looking statements, whether as a result of new information, future events or otherwise, as of any future date. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: March&nbsp;7, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">CVS HEALTH CORPORATION</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Colleen M. McIntosh</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U></U>Colleen M. McIntosh</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Senior Vice President and Corporate Secretary</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g535508g04p51.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g535508g04p51.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M 2(  A$! Q$!_\0 'P   04! 0$! 0$           $" P0%!@<("0H+_\0
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MEW61D",HW+RK'K7R)\3OVM/VF/@7\/\ P58_%/X$^%9/'GB[Q-#HOAZY\/\
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5P**_2Y8((0?)A2+/78@&?RHH __9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
